



Editorial

Almost no subject in medicine raises such passions as the treatment of localised prostate cancer. In this issue Jan Adolfsson puts forward the case for a conservative approach, at least in older patients. Many urologists and radiotherapists would take a diametrically opposed view. The problem lies in the lack of randomised controlled trials to help us judge with certainty which is the best treatment option for the individual patient. Until such data are available the debate will run and run. In this Journal we aim to take no particular stance, but rather provide a forum for open and honest discussion on all the most important issues.

In this second issue original scientific papers consider various aspects of benign prostatic hyperplasia (BPH), as well as the diagnosis and therapy of prostate cancer. The

days of unchallenged didactic pronouncements of self-styled 'experts' are now fast disappearing. We hope you will contribute your own thoughts and comments in the form of letters for publication and, in the near future, to the PCPD web site. Mark Feneley has kindly agreed to be our Internet editor to facilitate our move into cyberspace. Arie Beldegrun also provides us with up-to-the-minute news in 'What's Hot in the Prostate' a new section to which you are cordially invited to contribute.

Currently there is an unparalleled interest in all aspects of prostatic disorders. Join with us in making this new Journal an innovative vehicle for constructive advance in this most important disease area.

R Kirby, H Scher and M Brawer